Skip to Content

The Cooper Companies Inc COO

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Cooper Receives MiSight Approval in China; We Maintain Our Fair Value Estimate

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

Narrow-moat Cooper Companies reported fiscal third-quarter revenue of $763 million, an increase of 28% year over year on a constant-currency basis. Management raised the fiscal 2021 revenue guidance range to $2.893 million–$2.923 million and raised EPS guidance to $13.2–$13.4. The revised guidance is only slightly higher than our estimate for the year and does not impact our fair value estimate of $340 per share.

Read Full Analysis

Company Profile

Business Description

Cooper Companies operates two units: CooperVision and CooperSurgical. Accounting for approximately 75% of total sales, CooperVision is the the second- largest player in the oligopolistic contact lens market. Over 50% of CooperVision's sales are in international territories. The second unit, CooperSurgical, develops and manufactures diagnostic and surgical products for gynecologists and obstetricians, including the Paragard IUD, which Cooper acquired from Teva in 2017.

6101 Bollinger Canyon Road, Suite 500
San Ramon, CA, 94583
T +1 925 460-3600
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings Jul 31, 2021
Fiscal Year End Oct 31, 2021
Stock Type Slow Growth
Employees 12,000